Arctic Bioscience is a public limited company, incorporated in accordance with Norwegian law. Arctic Bioscience was listed on Euronext Growth, Oslo on 24 February 2021, under the ticker ABS.
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Get the latest news and stock exchange notifications from Arctic Bioscience by subscribing to our newsletter.
If you change your mind you can unsubscribe by following the link in the footer of any e-mail you receive from us. We will then delete your e-mail address from our register.